Ceryvyn Therapeutics Ltd (OPTEY)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Peers in Healthcare
Ceryvyn Therapeutics Ltd has no peer companies in this window.
Recent press releases
Ceryvyn Therapeutics Ltd has not issued a press release in this window.
SEC filings
All filings →Ceryvyn Therapeutics Ltd has not filed an SEC document in this window.
Insider trades
All insider trades →Ceryvyn Therapeutics Ltd has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Ceryvyn Therapeutics Ltd
All people →No officers or directors have been indexed for Ceryvyn Therapeutics Ltd.